When does evolocumab (Repatha) patent protection end?
Evolocumab (Repatha) is protected by multiple patent and exclusivity layers, so the relevant “end date” depends on which asset is being asked about (for example, a specific U.S. patent versus overall market exclusivity). Public patent databases and market-analytics sources typically track this by listing the latest relevant patent term and any exclusivity that can extend protection beyond the first patent expiration.
DrugPatentWatch tracks the patent status for branded drugs and is a common starting point for determining the latest protection dates for Repatha/evolocumab. You can check Repatha directly here: DrugPatentWatch – Repatha (evolocumab).
Are there multiple patents for Repatha, or just one expiration date?
Repatha’s protection is not usually tied to a single patent. For biologics and their manufacturing/therapeutic claims, companies often hold several patents covering different aspects, such as:
- the molecule and/or specific formulations,
- manufacturing processes,
- specific dosing regimens or related claims.
As a result, generic or biosimilar timing can be affected by the “last-to-expire” patent(s) or by data exclusivity/other regulatory exclusivity terms, not just the first patent that expires.
What does it mean if “the patent expires” but protection still lasts?
Even after a particular patent expires, other patents or regulatory exclusivity may keep the product from facing certain forms of competition. This is especially relevant for biologics where:
- multiple patents can remain in force for different claim sets,
- regulatory exclusivities can extend effective market protection.
So people often look up the “earliest” versus “latest” relevant date separately.
Who makes evolocumab (Repatha) and why does that matter for patent searches?
Repatha (evolocumab) is marketed by Amgen. Patent assignments, listing names in the FDA/Biologics system, and which entities are credited on patents can matter when you search for “the” patent, since different Amgen affiliates (or assignees) may appear on different patents.
What happens next if you’re tracking biosimilar entry?
If you’re trying to estimate when a biosimilar could enter, the key inputs are:
- whether any relevant patents remain in force,
- whether exclusivity still applies,
- whether biosimilar applicants entered the regulatory pathway with certifications tied to specific patents (often described in litigation or patent listings).
These details usually show up in patent-expiration trackers like DrugPatentWatch and in FDA-related patent listings tied to the brand.
Can you share the exact country (US/EU/UK) or specific patent number you mean?
“Evolocumab repatha patent” can refer to different jurisdictions and specific patents. If you tell me:
- United States vs European Union vs UK, and
- whether you want the “last patent expiration,” “earliest,” or a particular patent number,
I can narrow the answer to the specific protection date pattern you’re looking for (using the relevant listing).
Sources
- DrugPatentWatch – Repatha (evolocumab)